

MARRONE BIO INNOVATIONS INC
Form 8-K
June 03, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 29, 2014

MARRONE BIO INNOVATIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

2121 Second St. Suite A-107, Davis, CA

001-36030
(Commission

File Number)

20-5137161
(I.R.S. Employer

Identification No.)

95618

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (530) 750-2800

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 29, 2014, we held our Annual Meeting of Stockholders (the Annual Meeting) in Davis, California. Of the 19,740,341 shares of common stock outstanding and entitled to vote at the Annual Meeting, 13,906,982 shares were present at the Annual Meeting either in person or by proxy, constituting a quorum of 70.45%. Our stockholders considered and voted on the following proposals at the Annual Meeting:

(i) The holders of the our common stock elected two nominees to serve as Class I directors for three- year terms, ending at the time of the 2017 Annual Meeting of Stockholders (or until a successor is duly elected and qualified) pursuant to our Bylaws and the applicable laws of the State of Delaware.

The results of the voting were as follows:

| Name of Director | VOTES FOR | VOTES WITHHELD | BROKER NON-VOTES |
|-------------------------|------------------|-----------------------|-------------------------|
| Pamela G. Marrone, Ph.D | 9,017,988 | 271,696 | 4,617,298 |
| Les Lyman | 7,629,723 | 1,659,961 | 4,617,298 |

(ii) The holders of the our common stock ratified the appointment of Ernst & Young LLP as the Company s independent registered public accounting firm for the fiscal year ending December 31, 2014.

The results of the voting were as follows:

| | |
|-------------------------|------------|
| VOTES FOR: | 13,253,669 |
| VOTES AGAINST: | 651,682 |
| VOTES ABSTAINED: | 1,631 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARRONE BIO INNOVATIONS, INC.

Dated: June 2, 2014

By: /s/ Linda Moore
Linda V. Moore
Vice President, General Counsel and Secretary